Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.53 |
| ▸ | EPHX2 | P34913 | 4/20 | 0.52 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.50 |
| ▸ | HPGD | P15428 | 2/20 | 0.50 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.50 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.50 |
| ▸ | BLM | P54132 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.50 |
| ▸ | FAAH | O00519 | 2/20 | 0.49 |
| ▸ | CNR2 | P34972 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15124523 | 0.95 | CNR1 (0.57) | CNR1EPHX2ALDH1A1TRPV1MEN1 | |
| SCHEMBL15124524 | 0.95 | CNR1 (0.57) | CNR1EPHX2ALDH1A1TRPV1MEN1 | |
| SCHEMBL15124522 | 0.95 | CNR1 (0.57) | CNR1EPHX2ALDH1A1TRPV1MEN1 | |
| SCHEMBL15124015 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT | |
| SCHEMBL15124016 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT | |
| SCHEMBL15124286 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT | |
| SCHEMBL15124283 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT | |
| SCHEMBL25549752 | 0.93 | CNR1 (0.63) | CNR1EPHX2KDM4EALDH1A1HPGD | |
| SCHEMBL15124014 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT | |
| SCHEMBL15124284 | 0.93 | CNR1 (0.55) | CNR1EPHX2ALDH1A1MEN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NOVARTIS AG (CH) | 2023-05-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230158150-A1 | COMPOUND COMPRISING A NUCLEIC ACID AND A HALF-LIFE EXTENSION MOTIF | NSUN2, NSUN3, POLM | CNR1 4709/4885EPHX2 3717/4885KDM4E 2196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.